New York Times’ ‘Room For Debate’ Feature Discusses PrEP HIV Prevention Strategy

New York Times: Is a Pill Enough to Fight HIV?
“New federal guidelines urge gay men and others who have unprotected sex to take a daily dose of the drug Truvada, a regimen called pre-exposure prophylaxis (PrEP), to curb HIV infections and AIDS. Is promoting the use of the antiviral drug a good public health strategy, or will it encourage more to have unprotected sex?” The newspaper features opinion pieces from Michael Weinstein, president of the AIDS Healthcare Foundation; Renato Barucco, head of the Transgender Family Program at Community Healthcare Network in New York City; Larry Kramer, a gay rights advocate and playwright; Peter Acworth, founder and chief executive of; and Kenneth Mayer, a professor at Harvard Medical School, director of HIV prevention research at Beth Israel Deaconess Medical Center in Boston, and founder and medical research director of the Fenway Institute (6/17).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.